Global Information
회사소개 | 문의 | 비교리스트

죽상동맥경화증 : 파이프라인 리뷰

Atherosclerosis - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 232865
페이지 정보 영문 245 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


죽상동맥경화증 : 파이프라인 리뷰 Atherosclerosis - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 245 Pages

죽상동맥경화증은 플라크가 축적되어 동맥이 두꺼워지고 경화되는 질환입니다. 혈액순환을 방해하고 심각한 심혈관장애를 일으킵니다. 증상은 흉통, 사지 또는 동맥이 폐색된 부위의 통증, 호흡 곤란, 피로감, 의식 장애, 혈류 부족으로 인한 다리 근력 저하 등입니다.

죽상동맥경화증(Atherosclerosis) 치료제 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

서론

  • 조사 범위

죽상동맥경화증 개요

치료제 개발

치료제 평가

치료제 개발 참여 기업

약제 개요

휴지 상태의 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

부록

도표

LSH 17.07.24

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Atherosclerosis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Atherosclerosis - Pipeline by 13therapeutics Inc, H1 2020
  • Atherosclerosis - Pipeline by Abcentra LLC, H1 2020
  • Atherosclerosis - Pipeline by ABIONYX Pharma SA, H1 2020
  • Atherosclerosis - Pipeline by AdaptVac ApS, H1 2020
  • Atherosclerosis - Pipeline by AFFiRiS AG, H1 2020
  • Atherosclerosis - Pipeline by Allysta Pharmaceuticals Inc, H1 2020
  • Atherosclerosis - Pipeline by Amgen Inc, H1 2020
  • Atherosclerosis - Pipeline by Annexin Pharmaceuticals AB, H1 2020
  • Atherosclerosis - Pipeline by AptaBio Therapeutics Inc, H1 2020
  • Atherosclerosis - Pipeline by Artery Therapeutics Inc, H1 2020
  • Atherosclerosis - Pipeline by Asdera LLC, H1 2020
  • Atherosclerosis - Pipeline by AstraZeneca Plc, H1 2020
  • Atherosclerosis - Pipeline by Athera Biotechnologies AB, H1 2020
  • Atherosclerosis - Pipeline by Auxagen Inc, H1 2020
  • Atherosclerosis - Pipeline by Band Therapeutics LLC, H1 2020
  • Atherosclerosis - Pipeline by BBN Cardio Therapeutics, H1 2020
  • Atherosclerosis - Pipeline by Boehringer Ingelheim International GmbH, H1 2020
  • Atherosclerosis - Pipeline by Centeer BioTherapeutics Ltd Co, H1 2020
  • Atherosclerosis - Pipeline by CohBar Inc, H1 2020
  • Atherosclerosis - Pipeline by Corbus Pharmaceuticals Inc, H1 2020
  • Atherosclerosis - Pipeline by General Regeneratives Shanghai Ltd, H1 2020
  • Atherosclerosis - Pipeline by GenKyoTex SA, H1 2020
  • Atherosclerosis - Pipeline by Grindeks AS, H1 2020
  • Atherosclerosis - Pipeline by Innolife Co Ltd, H1 2020
  • Atherosclerosis - Pipeline by Inotrem SA, H1 2020
  • Atherosclerosis - Pipeline by Inspyr Therapeutics Inc, H1 2020
  • Atherosclerosis - Pipeline by Iproteos SL, H1 2020
  • Atherosclerosis - Pipeline by Jenrin Discovery Inc, H1 2020
  • Atherosclerosis - Pipeline by Kaleido Biosciences Inc, H1 2020
  • Atherosclerosis - Pipeline by KineMed Inc, H1 2020
  • Atherosclerosis - Pipeline by Kowa Co Ltd, H1 2020
  • Atherosclerosis - Pipeline by LG Chem Ltd, H1 2020
  • Atherosclerosis - Pipeline by LipimetiX Development Inc, H1 2020
  • Atherosclerosis - Pipeline by MetiMedi Pharmaceuticals Co Ltd, H1 2020
  • Atherosclerosis - Pipeline by Mperia Therapeutics Inc, H1 2020
  • Atherosclerosis - Pipeline by Novartis AG, H1 2020
  • Atherosclerosis - Pipeline by NuSirt Biopharma Inc, H1 2020
  • Atherosclerosis - Pipeline by Omeros Corp, H1 2020
  • Atherosclerosis - Pipeline by Pharmahungary Group, H1 2020
  • Atherosclerosis - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
  • Atherosclerosis - Pipeline by Repair Biotechnologies Inc, H1 2020
  • Atherosclerosis - Pipeline by Riparian Pharmaceuticals Inc, H1 2020
  • Atherosclerosis - Pipeline by Sansho Co Ltd, H1 2020
  • Atherosclerosis - Pipeline by Serene LLC, H1 2020
  • Atherosclerosis - Pipeline by Shin Poong Pharm Co Ltd, H1 2020
  • Atherosclerosis - Pipeline by Signablok Inc, H1 2020
  • Atherosclerosis - Pipeline by Tiara Pharmaceuticals Inc, H1 2020
  • Atherosclerosis - Pipeline by Underdog Pharmaceuticals Inc, H1 2020
  • Atherosclerosis - Pipeline by Vascular Biogenics Ltd, H1 2020
  • Atherosclerosis - Pipeline by VasThera Research Institute, H1 2020
  • Atherosclerosis - Pipeline by Vaxil Bio Therapeutics Ltd, H1 2020
  • Atherosclerosis - Pipeline by Vicore Pharma AB, H1 2020
  • Atherosclerosis - Pipeline by Wooridul Pharmaceutical Ltd, H1 2020
  • Atherosclerosis - Pipeline by XBiotech Inc, H1 2020
  • Atherosclerosis - Dormant Projects, H1 2020
  • Atherosclerosis - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Atherosclerosis - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Atherosclerosis - Dormant Projects, H1 2020 (Contd..3), H1 2020
  • Atherosclerosis - Dormant Projects, H1 2020 (Contd..4), H1 2020
  • Atherosclerosis - Dormant Projects, H1 2020 (Contd..5), H1 2020
  • Atherosclerosis - Dormant Projects, H1 2020 (Contd..6), H1 2020
  • Atherosclerosis - Dormant Projects, H1 2020 (Contd..7), H1 2020
  • Atherosclerosis - Dormant Projects, H1 2020 (Contd..8), H1 2020
  • Atherosclerosis - Discontinued Products, H1 2020
  • Atherosclerosis - Discontinued Products, H1 2020 (Contd..1), H1 2020
  • Atherosclerosis - Discontinued Products, H1 2020 (Contd..2), H1 2020

List of Figures

  • Number of Products under Development for Atherosclerosis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atherosclerosis - Pipeline Review, H1 2020, provides an overview of the Atherosclerosis (Cardiovascular) pipeline landscape.

Atherosclerosis (or arteriosclerotic vascular disease) is a condition where the arteries become narrowed and hardened due to an excessive build up of plaque around the artery wall. The disease disrupts the flow of blood around the body, posing serious cardiovascular complications. Symptoms of atherosclerosis are chest pain (angina), pain in the leg, arm, and anywhere else that an artery is blocked, shortness of breath, fatigue, confusion (if the blockage affects circulation to the brain) and muscle weakness in the legs from lack of circulation.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atherosclerosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Atherosclerosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atherosclerosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 1, 3, 7, 1, 36, 13 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 18 and 2 molecules, respectively.

Atherosclerosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Atherosclerosis (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Atherosclerosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Atherosclerosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Atherosclerosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Atherosclerosis (Cardiovascular)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Atherosclerosis (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Atherosclerosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Atherosclerosis - Overview
  • Atherosclerosis - Therapeutics Development
  • Atherosclerosis - Therapeutics Assessment
  • Atherosclerosis - Companies Involved in Therapeutics Development
  • Atherosclerosis - Drug Profiles
  • Atherosclerosis - Dormant Projects
  • Atherosclerosis - Discontinued Products
  • Atherosclerosis - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q